Please login to the form below

Not currently logged in
Email:
Password:

Asana appoints new chief medical officer

Louis Denis joins from Boehringer Ingelheim

Asana Biosciences has appointed Louis Denis as its new chief medical officer.

Denis is a medical oncologist with over 20 years of academic and industry experience in clinical cancer drug development.

He will be responsible for the overall strategic direction and medical oversight of clinical development of Asana's novel product candidates.

He said: “I am delighted to join Asana at this transformative time for the company.

“I look forward to working with the Asana team and its scientific advisory board to advance the company's broad portfolio of differentiated targeted therapies to help address major unmet medical needs.”

Denis has formerly held strategic and leadership positions at Boehringer-Ingelheim, where he headed the medical team, and Pfizer. 

Sandeep Gupta, president and chief executive officer of Asana Biosciences, said: “We are extremely pleased with the addition of Dr. Denis, a highly experienced physician and scientist, to our team. It represents a significant step in our evolution as an oncology-focused clinical development company.”

29th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics